GLP-1 Therapy After Bariatric Surgery in Chinese Patients With Obesity

Plain-language guide to NCT07633639: not phased non-randomized trial of Tirzepatide and Semaglutide, 200 participants. Who took part, design and what was measured.

Key Facts

Registry ID: NCT07633639
Phase: not phased
Status: recruiting participants
Start: 2026-05-01
Completion (planned or actual): 2028-05-01
Participants: 200 (estimated)
Design: non-randomized, open label (everyone knows who gets what), treatment
Conditions studied: Obesity
Results posted: not yet

What This Study Did, in Plain Language

What Was Tested

This registered not phased trial tested Tirzepatide and Semaglutide.

It had four arms (groups): LSG-Semaglutide group (experimental), LSG-Mazdutide group (experimental), LSG-Tirzepatide group (experimental) and LSG group (other).

The registry classes the interventions as combination product and procedure.

More on the Plan

Given the distinct advantages of both bariatric surgery and GLP-1RA therapy in weight and metabolic control, this study will combine these modalities into a comprehensive treatment strategy.

Who Took Part

The registry lists 200 planned participants were the target.

It was open to people of any sex aged from 18 years up to 60 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Patients undergoing initial laparoscopic sleeve gastrectomy (LSG). Obesity:BMI ≥30 kg/m². Metabolic comorbidities: Diagnosis of metabolic syndrome or type 2 diabetes mellitus (T2DM) meeting standard criteria. Age range: 18-60 years (inclusive). Informed consent: Willing participation with documented consent.

The full record lists 5 inclusion and 6 exclusion criteria; among the exclusions: recent glp-1ra use: treatment with glp-1 receptor agonists within 6 months preoperatively; prior bariatric surgery: history of any metabolic/bariatric surgical procedure; postoperative complications: requiring reoperation for severe complications (e.g., hemorrhage, anastomotic leak).

How the Study Was Run

It was run as a non-randomized, parallel-group and open-label study.

Groups ran in parallel: each of the participants stayed in one arm throughout.

Nothing was hidden in this open-label Tirzepatide study: the participants and staff both knew the treatment.

It started in 2026-05-01 with completion listed for 2028-05-01.

It ran at 1 site in China.

Its stated primary purpose is treatment.

What Was Measured

Primary outcome: Percentage of weight loss (time frame: Immediately postoperatively (Day 0), and at 1, 3, 6, and 12 months postoperatively).

It also tracked 26 secondary outcomes, for example Weight in kilograms, Waist circumference in centimeters, Hip circumference in centimeters, Blood pressure, Serum creatinine and Glomerular filtration rate.

What This Means in Plain Language

Put simply, this is a not phased, non-randomized trial of Tirzepatide and Semaglutide in 200 people.

It is still recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Tirzepatide compound page and the Semaglutide compound page, all human trials.

Our Notes on the Compounds

Tirzepatide: A prescription peptide medicine that acts on both the GIP and GLP-1 receptors; Mounjaro and Zepbound contain the same active ingredient.

Semaglutide: The active ingredient in several prescription GLP-1 receptor agonist medicines (Ozempic, Wegovy, oral tablets).

Mazdutide: A dual GLP-1 and glucagon receptor agonist with approvals announced in China for weight management and type 2 diabetes.

Source: ClinicalTrials.gov record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.